Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254822 | 0.83 | KDM4E (0.46) | KDM4EALDH1A1HSD17B10NOTUMKMT2A | |
| SCHEMBL11336303 | 0.78 | L3MBTL1 (0.49) | KDM4EALDH1A1KMT2ARAB9ANPC1 | |
| SCHEMBL29048096 | 0.78 | KDM4E (0.43) | KDM4EALDH1A1HSD17B10NOTUMKMT2A | |
| SCHEMBL1047908 | 0.74 | SMN1; SMN2 (0.50) | KDM4EALDH1A1HSD17B10KMT2ANPC1 | |
| SCHEMBL197298 | 0.74 | SMN1; SMN2 (0.50) | KDM4EALDH1A1HSD17B10RAB9ANPC1 | |
| SCHEMBL3236165 | 0.74 | RAB9A (0.50) | KDM4EALDH1A1HSD17B10NOTUMKMT2A | |
| SCHEMBL16733990 | 0.74 | KDM4E (0.45) | KDM4EALDH1A1HSD17B10NOTUMKMT2A | |
| SCHEMBL10978584 | 0.74 | GABRA1 (0.41) | KDM4EALDH1A1HSD17B10KMT2APKM | |
| SCHEMBL12806392 | 0.74 | CYP1A2 (0.44) | KDM4EALDH1A1HSD17B10HPGDTSHR | |
| SCHEMBL10925713 | 0.73 | ALDH1A1 (0.44) | KDM4EALDH1A1HSD17B10KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2010-09-16 | — | — | US | claimed |
| US-7705158-B2 | Inhibitors of ion channels | ICAGEN, INC. (US) | 2010-04-27 | — | — | US | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8338608-B2 | Inhibitors of ion channels | ICAGEN INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7705158-B2 | Inhibitors of ion channels | ICAGEN, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| EP-1945029-A2 | INHIBITORS OF ION CHANNELS | Icagen, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | ICAGEN (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2007056099-A2 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | KDM4E 1973/4885ALDH1A1 3113/4885HSD17B10 3346/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | KDM4E 4854/4885ALDH1A1 355/4885HSD17B10 467/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | KDM4E 4578/4885ALDH1A1 412/4885HSD17B10 363/4885 |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | KDM4E 1973/4885ALDH1A1 3113/4885HSD17B10 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.